Northrim BanCorp, Inc. Declares Quarterly Cash Dividend of $0.16 per Share ANCHORAGE, Alaska, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Northrim BanCorp, Inc. (NASDAQ: NRIM) today announced that the Board of Directors declared a regular quarterly cash dividend of $0.16 per share. The dividend will be payable on March 13, 2026, to shareholders of record at the close of business on March 5, 2026. “We are pleased to announce a quarterly dividend of $0.16 per share, as we continue to provide returns to our shareholders,” said Mike Huston, President and CEO. At the stock price of $25.25 per share at ...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Jan. 23, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 14,250 shares of its common stock to five newly-hired employees, with a grant date of January 20, 2026 (the "Grant Date"). The restricted stock units were granted pu...
Northrim BanCorp Earns $12.4 Million, or $0.55 Per Diluted Share, in Fourth Quarter 2025, and $64.6 Million, or $2.87 Per Diluted Share, for the Year Ended December 31, 2025 ANCHORAGE, Alaska, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Northrim BanCorp, Inc. (NASDAQ:NRIM) (“Northrim” or the “Company”) today reported net income of $12.4 million, or $0.55 per diluted share, in the fourth quarter of 2025, compared to $27.1 million, or $1.20 per diluted share, in the third quarter of 2025, and $10.9 million, or $0.49 per diluted share, in the fourth quarter a year ago. The decrease in the fourth quart...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Dec. 12, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 3,600 shares of its common stock to three newly-hired employees, with a grant date of December 9, 2025 (the "Grant Date"). The restricted stock units were granted pu...
Northrim BanCorp, Inc. Declares Quarterly Cash Dividend of $0.16 per Share ANCHORAGE, Alaska, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Northrim BanCorp, Inc. (NASDAQ: NRIM) today announced that the Board of Directors declared a regular quarterly cash dividend of $0.16 per share. The dividend will be payable on December 26, 2025, to shareholders of record at the close of business on December 18, 2025. “We are pleased to announce a quarterly dividend of $0.16 per share, as we continue to provide returns to our shareholders,” said Mike Huston, President and CEO. At the stock price of $25.05 per sh...
Northrim BanCorp, Inc. Announces Completion of $60.0 Million Subordinated Notes Offering ANCHORAGE, Alaska, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Northrim BanCorp, Inc. (NASDAQ: NRIM). (“Northrim” or the “Company”) today announced the completion of its private placement of $60.0 million in aggregate principal amount of 6.875% Fixed-to-Floating Rate Subordinated Notes due 2035 (the “Notes”) to certain qualified institutional buyers and institutional accredited investors. The Notes bear interest at a fixed annual rate of 6.875% for the first five years and will reset quarterly thereafter to th...
TELA Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference MALVERN, Pa., Nov. 19, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in Piper Sandler’s 37th Annual Healthcare Conference. TELA’s management is scheduled to present at Piper Sandler’s 37th Annual Healthcare Conference at 2:30 pm ET on December 3rd, 2025. Interested parties can access the live and archived webcast at . About TELA Bio, In...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of (i) restricted stock units covering 30,200 shares of its common stock to seventeen newly-hired employees and (ii) an option to purchase 25,000 shares of its common stock to one employee, with a gra...
TELA Bio Announces Pricing of $13.0 Million Underwritten Registered Direct Offering of Common Stock and Pre-Funded Warrants MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the pricing of an underwritten registered direct offering of 4,189,000 shares of its common stock at a price of $1.11 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase 7,523,000 shares of common stock at an offering p...
TELA Bio Reports Third Quarter 2025 Financial Results and Refinancing and Upsizing of Credit Facility MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights Revenue of $20.7 million, a 9% increase from the third quarter of 2024Revised full year 2025 revenue guidance of at least 16% growth over full year 2024 Recent Strategic Highli...
TELA Bio to Announce Third Quarter 2025 Financial Results MALVERN, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report third quarter 2025 financial results on Thursday, November 13, 2025. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Third Quarter Earnings Conference Call and Webcast DetailsInve...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.